Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group Study

Journal of the National Cancer Institute

Volumn 89, Issue 5, 1997, Pages 373-380

  Bowman, Laura C ^a,b   Castleberry, Robert P ^c   Cantor, Alan ^d   Joshi, Vijay ^e   Cohn, Susan L ^f   Smith, E Ide ^g   Yu, Alice ^h   Brodeur, Garrett M ⁱ   Hayes, F Ann ^j   Look, A Thomas ^a,k  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e EAST CAROLINA UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j AMGEN INC   (United States)

^k UNIVERSITY OF TENNESSEE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; TENIPOSIDE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG SENSITIVITY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INFANT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHROTOXICITY; NEUROBLAST; NEUROBLASTOMA; ONCOGENE; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PLOIDY; PROGNOSIS; RISK;

EID: 0031041101     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.5.373     Document Type: Article

References (41)

1. Pui CH, Crist WM. Biology and treatment of acute lymphoblastic leukemia. J Pediatr 1994;124:491-503.
2. Crist WM, Kun LE. Common solid tumors of childhood. N Engl J Med 1991;324:461-71.
3. Saccani Jotti G, Bonadonna G. The pathologist and clinical oncologist: a new effective partnership in assessing tumor prognosis. Eur J Cancer Clin Oncol 1989;25:585-98.
4. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definitions of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-16.
5. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JS, Shuster JJ, et al. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer 1992;69:2197-211.
6. Hayes FA, Green AA, Mauer AM. Correlation of cell kinetic and clinical responses to chemotherapy in disseminated neuroblastoma. Cancer Res 1977;37:3766-70.
7. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott, 1993:739-68.
8. Schnipper L. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986;314:1423-31.
9. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143-9.
10. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-5.
11. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
12. Hayes FA, Green AA, Casper J, Cornet J, Evans WE. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. Cancer 1981;48:1715-8.
13. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
14. Nitschke R, Smith EI, Shochat S, Altshuler G, Travers H, Shuster JJ, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group study. J Clin Oncol 1988;6:1271-9.
15. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971;27:374-8.
16. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
17. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
18. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983;132: 6-13.
19. Quinn JJ, Altman AJ, Frantz CN. Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J Pediatr 1980;97:89-91.
20. Hann HL, Evans AE, Siegel SE, Wong KY, Sather H, Dalton A, et al. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 1985;45:2843-8.
21. Green AA, Hayes FA, Hustu HO. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer 1981;48:2310-7.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Mehta C, Patel N. StatXact user manual. Cambridge (MA): CYTEL Software Corporation, 1992.
24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;35: 585-612.
25. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Oxford (UK): Oxford Univ Press, 1990.
26. Bowman LC, Hancock ML, Santana VM, Hayes FA, Kun L, Parham DM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St. Jude Children's Research Hospital experience, 1962 to 1988. J Clin Oncol 1991;9:1599-608.
27. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology [editorial]. Br J Cancer 1994;69:979-85.
28. Castleberry RP, Shuster JJ, Altshuler G, Smith EI, Nitschke R, Winick N, et al. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group study. J Clin Oncol 1992;10:1299-304.
29. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-8.
30. Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30.
31. Shuster JJ, McWilliams NB, Castleberry R, Nitschke R, Smith EI, Altshuler G, et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 1992;15:295-303.
32. Kumagai M, Manabe M, Pui CH, Behm FG, Raimondi SC, Hancock ML, et al. Stroma-supported culture of childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996;97:755-60.
33. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54.
34. Bourhis J, De Vathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991;51:33-6.
35. Evans AE, Baum E, Chard R. Do infants with IV-S neuroblastoma need treatment? Arch Dis Child 1981;56:271-4.
36. Kretschmar CS, Frantz CN, Rosen EM, Cassady JR, Levey R, Sallan SE. Improved prognosis for infants with stage IV neuroblastoma. J Clin Oncol 1984;2:799-803.
37. Castleberry RP, Cantor A, Green AA, Joshi V, Berkow RL, Buchanan GR, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1994;12: 1616-20.
38. 2): a report from the LMCE group. Adv Neuroblastoma Res 1988;2:573-82.
39. Hartman O, Benhamou F, Beaujean C, Kalifa C, Lejars O, Patte C, et al. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987;5:1205-11.
40. Cheung NK. Immunotherapy. Neuroblastoma as a model. Pediatr Clin North Am 1991;38:425-41.
41. Brenner MK, Furman WC, Santana VM, Bowman L, Meyer W. Phase I study of cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. Hum Gene Therapy 1992;3: 665-76.